Home › Funds › Soleus Capital Management, L.P. › ANL
Soleus Capital Management, L.P. position in ANL
ADLAI NORTYE GROUP LTD · Health Care
Soleus Capital Management, L.P. reported holding 1,272,355 shares of ANL (ADLAI NORTYE GROUP LTD) in its Q3 2026 13F filing — a position valued at US$20.4M, representing 0.72% of its reported portfolio and ranking #32 among its reported holdings. Soleus Capital Management, L.P. has disclosed ANL holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How Soleus Capital Management, L.P.'s ANL position evolved
Soleus Capital Management, L.P. first disclosed a stake in ANL in Q2 2026 at 405,523 shares (US$4.7M). The position peaked in Q3 2026 at 1,272,355 shares, worth US$20.4M. Across 2 filings, Soleus Capital Management, L.P. increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 1,272,355 shares valued at US$20.4M — an increase of 866,832 shares quarter over quarter.. Notable position changes include a 214% increase in Q3 2026 (shares fell 37% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2026 | 405.52K | $4.66M | New |
| Q3 2026 | 1.27M | $20.36M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ANL and 13F data
ANL (ADLAI NORTYE GROUP LTD) is a Health Care company. 53 other funds we track also report a position in ANL — the largest reported positions include Cormorant Asset Management, LP (US$63.7M), Venrock Adviser, LLC (US$51.4M), MPM BioImpact LLC (US$31.3M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ANL
- Cormorant Asset Management, LP 3.98M sh · $63.65M · Q3 2026
- Venrock Adviser, LLC 3.21M sh · $51.40M · Q3 2026
- MPM BioImpact LLC 1.96M sh · $31.31M · Q3 2026
- PERCEPTIVE ADVISORS LLC 1.66M sh · $26.57M · Q3 2026
- Casdin Capital 1.25M sh · $20.00M · Q3 2026
- ADAR1 Capital Management, LLC 997.36K sh · $15.96M · Q3 2026
- Octagon Capital Advisors LP 934.72K sh · $14.96M · Q3 2026
- Squadron Capital Management LLC 764.88K sh · $12.24M · Q3 2026
- SUPERSTRING CAPITAL MANAGEMENT LP 588.42K sh · $9.41M · Q3 2026
- BOONE CAPITAL MANAGEMENT LLC 258.39K sh · $4.13M · Q3 2026
- DAFNA Capital Management LLC 232.76K sh · $3.72M · Q3 2026
- SILVERARC CAPITAL MANAGEMENT, LLC 216.62K sh · $3.47M · Q3 2026
More on Soleus Capital Management, L.P.
FAQ
How long has Soleus Capital Management, L.P. held ANL?
Soleus Capital Management, L.P. has disclosed ANL holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
What is Soleus Capital Management, L.P.'s current position in ANL?
As of Q3 2026, Soleus Capital Management, L.P. holds 1.27M shares of ANL (ADLAI NORTYE GROUP LTD), valued at $20.36M, representing 0.72% of its reported portfolio and ranking #32.
Has Soleus Capital Management, L.P. been buying or selling ANL?
In the latest 13F filing (Q3 2026), Soleus Capital Management, L.P. increased its position in ANL. The position peaked in Q3 2026 at 1.27M shares.
Which other funds hold ANL?
Other major institutional holders of ANL include Cormorant Asset Management, LP, Venrock Adviser, LLC, MPM BioImpact LLC, among 53 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.